In conclusion, we successfully developed and validated a result visualization and interpretation tool for a neurocognitive blood test including the markers P‐tau181, GFAP, and NfL, which is ready for testing in the real‐world clinical dementia settings. This evidence concerns the gene NEFL and dementia.